Fusion Pharmaceuticals' (FUSN) "Hold" Rating Reaffirmed at TD Cowen

Fusion Pharmaceuticals (NASDAQ:FUSN - Get Free Report)'s stock had its "hold" rating reiterated by analysts at TD Cowen in a note issued to investors on Tuesday, Benzinga reports.

Several other equities research analysts have also recently issued reports on the company. Jefferies Financial Group reaffirmed a "hold" rating and issued a $21.00 target price (up from $10.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Wedbush cut Fusion Pharmaceuticals from an "outperform" rating to a "neutral" rating and set a $24.00 price objective on the stock. in a report on Tuesday, March 19th. B. Riley lowered shares of Fusion Pharmaceuticals from a "buy" rating to a "neutral" rating and raised their target price for the company from $13.00 to $23.00 in a report on Wednesday, March 20th. Oppenheimer boosted their price target on shares of Fusion Pharmaceuticals from $13.00 to $15.00 and gave the stock an "outperform" rating in a research report on Friday, January 5th. Finally, Jonestrading reiterated a "hold" rating on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $20.25.

Fusion Pharmaceuticals Price Performance

Shares of Fusion Pharmaceuticals stock traded down $0.02 on Tuesday, hitting $21.26. 550,862 shares of the company traded hands, compared to its average volume of 2,104,842. Fusion Pharmaceuticals has a 52 week low of $2.31 and a 52 week high of $21.55. The business has a 50-day simple moving average of $15.48 and a 200 day simple moving average of $9.54. The company has a debt-to-equity ratio of 0.16, a quick ratio of 15.01 and a current ratio of 15.01. The stock has a market capitalization of $1.80 billion, a P/E ratio of -14.46 and a beta of -0.73.

Fusion Pharmaceuticals (NASDAQ:FUSN - Get Free Report) last posted its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. Research analysts expect that Fusion Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in FUSN. Signaturefd LLC raised its position in Fusion Pharmaceuticals by 883.0% in the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company's stock worth $28,000 after purchasing an additional 2,649 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Fusion Pharmaceuticals by 2,064.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company's stock worth $29,000 after buying an additional 2,869 shares during the period. Geode Capital Management LLC raised its holdings in shares of Fusion Pharmaceuticals by 20.8% in the second quarter. Geode Capital Management LLC now owns 30,374 shares of the company's stock worth $142,000 after buying an additional 5,238 shares during the period. New York State Common Retirement Fund bought a new stake in shares of Fusion Pharmaceuticals during the 4th quarter worth approximately $64,000. Finally, Renaissance Technologies LLC boosted its holdings in Fusion Pharmaceuticals by 39.9% during the 4th quarter. Renaissance Technologies LLC now owns 23,500 shares of the company's stock valued at $74,000 after acquiring an additional 6,700 shares during the period. Hedge funds and other institutional investors own 72.85% of the company's stock.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.